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AbstrAct:
Better understanding the mechanisms underlying the metastatic process is 
essential to developing novel targeted therapeutics. Recently, invadopodia have 
been increasingly recognized as important drivers of local invasion in metastasis. 
Invadopodia are basally-localized, actin-rich structures that concentrate protease 
activity to areas of the cell in contact with the extracellular matrix. We recently 
found that the transcription factor Twist1, a central regulator of the epithelial-
mesenchymal transition (EMT), promotes invadopodia formation via upregulation 
of platelet-derived growth factor receptor (PDGFR) expression and activity. This 
finding, combined with other investigations into the mechanisms of invadopodia 
formation, reveal several novel targets for clinical inhibition of invadopodia. 
Here, we provide an overview of clinically-relevant targets for intervention in 
invadopodia, including Src signaling, PDGFR signaling, and metalloprotease activity.
breAst cAncer metAstAsis, emt, 
And the stAte of therApeutic 
interventions
Breast cancer is the most common invasive cancer 
among women worldwide, with virtually all patients 
succumbing to not the primary disease, but distant 
metastases[1, 2]. Metastasis, the spread of cancer cells 
from the primary tumor to distant organs, is a multistep 
process in which cancer cells must invade through 
the extracellular matrix (ECM), intravasate into the 
bloodstream, survive transport through the circulatory 
system, and finally extravasate at distant organs[3]. As 
metastatic breast cancer is largely considered an incurable 
disease, better understanding the metastatic process and 
its regulation has the potential to not only identify new 
prognostic markers but also develop targeted therapeutic 
regimens.
Recently, aberrant activation of a developmental 
program termed the epithelial-mesenchymal transition 
(EMT) has been recognized as an important driver of the 
metastatic process[4].EMT is a conserved developmental 
process in which epithelial cells lose E-cadherin-mediated 
junctions and apical-basal polarity and become motile and 
invasive [5]. This program is accompanied by expression 
changes in a host of genes, among which genes associated 
with epithelial characteristics (E-cadherin and ZO-1) are 
downregulated while others associated with mesenchymal 
cells (smooth muscle actin, vimentin, and N-cadherin) are 
upregulated. A group of transcription factors, including 
Twist1, Snai1, Snai2, Zeb1, and Zeb2, play key roles in 
driving EMT during tumor metastasis[6, 7]. 
Current therapeutic standards for breast cancer 
involve surgical resection of the tumor supplemented 
with radiation therapy and chemotherapy[8]. Cytotoxic 
drugs and hormone-blocking therapeutics are the most 
often used chemotherapeutics, generally chosen for their 
effects on cell growth and apoptosis.  Generation of new 
therapeutic agents targeting invasion and metastasis have 
the potential to improve survival in populations that do 
not respond well to conventional therapies. Despite the 
growing evidence linking EMT to metastasis in breast 
and other cancers, therapeutically targeting EMT may 
be difficult. Directly inhibiting the transcription factors 
that drive EMT is currently infeasible, as targeting large 
binding interfaces is not amenable to small-molecule 
inhibition[9, 10]. Instead, downstream targets of these 
transcription factors essential for their role in invasion 
and metastasis are more realistic targets of therapeutic Oncotarget 2011; 2:  562 - 568 563 www.impactjournals.com/oncotarget
intervention.
twist1 And invAdopodiA
Although the role of EMT in metastasis is gradually 
becoming clearer, the exact molecular mechanisms 
underlying how EMT induces local invasion and 
metastasis are still not well understood[11]. Disruption of 
epithelial cell-cell contact is necessary for metastasis, but 
it is not sufficient[12]. We therefore sought to determine 
what pathways or mechanisms Twist1 induces to drive 
active local invasion and metastasis. We did not observe 
significant changes in secreted proteolytic activity in cells 
overexpressing Twist1, although they gained the ability to 
invade through Matrigel and metastasize to the lung in a 
subcutaneous tumor model[7]. We therefore hypothesized 
that Twist1 induces local invasion and eventual metastasis 
by inducing the formation of membrane protrusion 
structures called invadopodia.
Invadopodia are actin-rich protrusions that localize 
proteolytic activity to areas of the cell in contact with 
extracellular  matrix(ECM)[13-15].  Invadopodia  are 
observed  in  many  invasive  cancer  cell  lines  [16].    A 
wide variety of actin-interacting proteins and scaffolding 
proteins are involved in invadopodia formation, including 
cortactin,  Tks5,  fascin,  N-WASP,  and  Arp2/3[17].  In 
particular, the actin-bundling protein cortactin and the 
adaptor proteins Tks4/5appear to play integral roles in 
invadopodia formation[18, 19]. Both metalloproteases 
and serine proteases localize to invadopodia, including 
both secreted (MMP2 and MMP9) and transmembrane 
proteases  (MT1-MMP,  ADAM12,  FAPα,  and  DPP-iv)
[20].  Src kinase activity and phosphorylation of Tks4 [21], 
Tks5[18], and cortactin[19]are absolute requirements for 
invadopodia formation. Upregulation of invadopodia 
formation by Twist1 would therefore present a novel 
mechanism by which Twist1 could induce local invasion 
without changing secreted protease activity[22].
In order to investigate whether Twist1 was necessary 
for invadopodia, we generated knockdowns of Twist1 
in 168FARN and 4T1 cell lines, two mouse mammary 
carcinoma cell lines that express high levels of Twist1. 
By staining for markers of invadopodia (colocalization 
of F-actin with either cortactin or Tks5) we found that 
knockdown of Twist1 significantly reduced invadopodia 
formation  in  both  168FARN  and  4T1  cells[23]. 
Importantly, knockdown of Twist1 also dramatically 
reduced ECM degradation.Similar analyses in normal 
mammary epithelial cells overexpressing Twist1 
demonstrated that Twist1 was also sufficient to promote 
invadopodia formation and function. Importantly, 
Twist1-inducedinvadopodia formation requires both 
metalloprotease and Src-kinase activities, consistent with 
their known roles in invadopodia.
twist1 induces invAdopodiA 
formAtion by upregulAting 
PDGFRα
We  were  therefore  interested  in  the  mechanism 
by  which  Twist1  was  both  necessary  and  sufficient 
for invadopodia formation. None of the structural 
or enzymatic proteins found in invadopodia that we 
investigated,  including  Tks5,  cortactin,and  MT1-MMP, 
were  transcriptionally  regulated  by  Twist1.  We  did, 
however, observe a significant upregulation of Src kinase 
activation upon Twist1 expression. Microarray analysis of 
genes upregulated by Twist1 revealed that only one family 
of growth factor receptors upstream of Srcactivation 
was induced by Twist1: platelet-derived growth factor 
receptors (PDGFR) α and β. PDGFRα, in particular, was 
immediately and dramatically upregulated. Importantly, 
PDGFRα was phosphorylated and activated under normal 
culture conditions, implying the existence of an autocrine 
loop upon Twist1 activation.
There are two PDGFRs, PDGFRα and β, which differ 
primarily in their responsiveness to PDGF ligands[24]. 
In mammalian systems, PDGFR expression is abundant 
in mesenchymal and vascular tissues and is particularly 
involved in angiogenesis[25, 26]. Importantly, PDGFRs 
are directly upstream of Src kinase activity[27]. Upon 
stimulation by their ligands, the receptors dimerize and 
can directly activate Src kinase[28]. PDGFR signaling has 
previously been implicated as required for metastasis in 
a TGF-β-induced EMT model, although the mechanism 
for this inhibition was not clearly understood[29]. 
Encouragingly,  a  previous  study  found  that  PDGFR 
activation increased invadopodia formation in vascular 
smooth muscle cells[30].
Knockdown or inhibition of PDGFRα with a mouse 
monoclonal  blocking  antibody  significantly  reduced 
Twist1-induced invadopodia formation and function. 
Chromatin immunoprecipitation and luciferase reporter 
assays  also  revealed  that  PDGFRα  was  a  direct  target 
of  Twist1.  Activation  of  PDGFR  signaling  by  Twist1 
therefore appeared to be a direct requirement for Twist1-
mediated invadopodia formation.
InvaDoPoDIa  anD  PDGFRα  aRe 
necessAry for metAstAsis And 
implicAted in humAn breAst 
cAncer
To better understand the role of invadopodia and 
PDGFRα  in  metastasis,  we  utilized  a  subcutaneous 
tumor implantation model in which Twist1-expressing 
human  breast  tumor  cells  carrying  shRNAs  against 
PDGFRα or Tks5 were injected subcutaneously in nude 
mice. Knockdown of Tks5, an essential invadopodia 
component protein with no other known functions, 
allowed us to test whether invadopodia were required for Oncotarget 2011; 2:  562 - 568 564 www.impactjournals.com/oncotarget
Twist1-mediated  metastasis.  Knockdown  of  PDGFRα 
was used to determine whether PDGF signaling induced 
by Twist1 for invadopodia formation was required for 
metastasis. Although no significant differences in growth 
rate were observed, both Tks5 and PDGFRα knockdowns 
dramatically suppressed local invasion, with the primary 
tumors remaining relatively well-encapsulated in a layer 
of fibrotic tissue. In contrast, tumors expressing control 
knockdown constructs invaded through the local ECM, 
often  as  single  cells.  Furthermore,  knockdown  of  both 
Tks5 and PDGFRα significantly reduced dissemination to 
the lungs, as measured by quantification of GFP-positive 
puncta in the lungs.
In microarray data sets of human breast cancer tumor 
samples, we found a strong correlation between Twist1 
and  PDGFRα  expression,  with  PDGFRα  consistently 
ranking within the top 1% of genes correlated with 
Twist1. Furthermore, in a Stage II breast cancer tissue 
array from the National Cancer Institute coexpression of 
Twist1  and  PDGFRα  was  significantly  associated  with 
patient survival, indicating the importance of this pathway 
in human breast tumor progression. 
Druggable targets regulating invadopodia formation 
and function
The connection between Twist1, PDGFR signaling, 
and invadopodia is exciting as it highlights several 
new therapeutic targets for targeting local invasion in 
the  metastatic  process.  Namely,  PDGFRα,  Src,  and 
metalloproteases localized in invadopodia are appealing, 
druggable targets for targeting invasion in breast cancer 
metastasis  (see  Figure).  As  metastasis  may  occur 
via invadopodia-independent mechanisms in patient 
populations, Twist1 and PDGFRα coexpression may be 
appealing markers for patient stratification for treatment 
regimens targeting invadopodia.
PDGFRα and eGFR
As a direct target of Twist1 tightly associated with 
survival in human breast cancer patient tissue samples, 
PDGFRα is an especially appealing target for therapeutic 
intervention in breast cancer metastasis. The most well-
known and studied PDGFR inhibitor is imatinib mesylate 
(Gleevec,  Novartis),  which  also  inhibits Abl  and  c-Kit 
tyrosine kinases[31]. Data from clinical trials involving 
use of imatinib in advanced breast cancers has been 
discouraging  with  no  clear  objective  responses[32]. 
If  PDGFR  signaling  is  important  for  invasion  and 
metastasis, however, improved survival in these patients 
with late stage disease would be unlikely as the cancer had 
already widely metastasized. Often severe gastrointestinal 
side effects of imatinib treatment also severely limited its 
utility in at least one trial[33]. Another tyrosine kinase 
inhibitor,  Sunitinib  (Sutent,  Pfizer),  targets  PDGFRs, 
VEGFs, Kit, RET, and CSF[33]. Encouragingly, Sunitinib 
is much better tolerated and has had some effectiveness in 
preliminary clinical trials of metastatic breast cancer[34]. 
The  promiscuous  inhibitory  profile  of  Sunitinib  makes 
it  difficult  to  determine  whether  its  effects  on  disease 
outcome are through inhibition of PDGFRs. In light of our 
discovery, it is important to examine patient tumor samples 
to determine whether Sunitinib suppresses invadopodia 
Recent research in our lab revealed that Twist1 directly induces transcription of PDGFRα. Upregulation of PDGFRα 
leads to an increase in Src kinase activity that induces the formation or stabilization of invadopodia by phosphorylation of invadopodia 
component proteins by Src kinase. Invadopodia formation involves discrete steps in which formation of the F-actin core is an early 
event, followed by recruitment and phosphorylation of invadopodia component proteins like cortactin and Tks5 before proteases are 
recruited to the mature invadopodia. Promising targets for chemical inhibition include [1] PDGFR signaling, [2] Src kinase activity, and [3] 
metalloprotease activity at invadopodia (including MMP2, MMP9, and MT1-MMP).Oncotarget 2011; 2:  562 - 568 565 www.impactjournals.com/oncotarget
and local invasion.  To truly understand the utility of these 
novel inhibitors in breast cancer, it will be necessary to 
identify patient populations that will respond best to the 
therapy.  Development  of  more  specific  inhibitors  that 
target  only  PDGFRs,  including  humanized  monoclonal 
antibodies, may address some of the side effects due to 
off targeting.
Epidermal growth factor receptor (EGFR) signaling 
is also known to play an important role in regulation of 
invadopodia formation. The most characterized role of 
EGFR signaling in invadopodia is its function upstream 
of Src activation[35].  HER-2 (human epidermal growth 
factor receptor 2) status is an important clinical marker for 
treatment, with about 30% of patients presenting increased 
levels of HER-2expression[33]. Patients that are HER-2 
positive are considered candidates for treatment with HER-
2 inhibitors, including trastuzumab (Herceptin, Genentech) 
and lapatinib (Tykerb/Tyverb GSK)[36]. Recently, new 
small  molecule-based  therapeutics  targeting  EGFR, 
including erlotinib (Tarceva, OSI Pharmaceuticals), have 
proven useful in other cancers with upregulation of EGFR 
signaling[37].  OSI  Pharmaceuticals  investigated  the 
properties of cancer cells resistant to EGFR inhibition and 
found that this subpopulation of cells displayed properties 
of EMT, including an increased dependence on PDGFR 
signaling[38, 39]. During EMT, PDGFR signaling may 
largely supplant or supplement the role of EGFR signaling 
in promoting invadopodia formation in breast cancer cells. 
This also suggests that the EMT process may play roles 
in not only mediating local invasion and metastasis, but 
also providing an escape mechanism from growth factor 
inhibition. 
Src and its effectors
As the first proto-oncogene discovered, there is a 
large body of research focusing on not only the role of 
Src in cancer but also potential therapeutic interventions. 
It is generally recognized that Src plays multiple roles in 
carcinomas, promoting both proliferation and survival and 
driving invasion[40]. The essential role of Src activation in 
invadopodia formation suggests that Src inhibitors should 
effectively prevent invadopodia formation and ECM 
degradation in tumors. Several Src inhibitors are already in 
the clinic and used to treat chronic myelogenous leukemia 
by virtue of their ability to also inhibit Abl kinase[41]. 
Src activity is also upregulated in a wide variety of solid 
cancers, including colon, breast, gastric, and ovarian 
cancers[42]. Several pharmaceutical companies have 
therefore developed Src kinase inhibitors with varying 
levels of success. Most Src inhibitors that have progressed 
to clinical trials in solid tumors (Dasatinib, Bristol-
Meyers Squibb; Saracatinib, AstraZeneca; and Bosutinib, 
Wyeth) work by competitively binding the ATP-binding 
site of Src[40]. Initial results from clinical trials of Src 
inhibitors in breast cancer have been mixed, with most 
single-agent trials resulting in no significant differences 
in survival or progression[43]. Combination therapeutics 
have resulted in more positive, although modest, effects 
[42].It is important to note, however, that all clinical 
trials regarding Src inhibitors in breast cancer have been 
conducted in unselected patient populations and the main 
readout for effectiveness has been tumor size and growth, 
not invasion. There are some indications, however, that 
patient  stratification  can  predict  responsiveness  to  Src 
kinase inhibition[44]. Novel Src inhibitors targeting the 
peptide binding site of Src rather than the ATP-binding site 
(KX2-391,  Keryx  Biopharmaceuticals)  may  also  prove 
to be more effective in solid tumors, although clinical 
trials involving these compounds are still preliminary and 
underway[45].
Interestingly, a recent publication elucidated a 
detailed mechanisms for Src-kinase induced invadopodia 
formation[35].  Rather  than  directly  phosphorylating 
cortactin,  Src  instead  activates  the  Abl-related  non-
receptor  tyrosine  kinase  Arg  that  is  responsible  for 
cortactin phosphorylation. In this system, cortactin 
tyrosine phosphorylation is transiently required for 
cortactin-mediated actin polymerization in invadopodia. 
This is particularly interesting, as Gleevec, a drug 
often used to target PDGFR signaling, also inhibits Arg 
activity[31]. The promiscuity of Gleevec could therefore 
target multiple levels of the signaling pathways regulating 
invadopodia formation, making it a promising target in 
selected patient populations[46].
Metalloproteases
Several metalloproteases are enriched at invadopodia, 
including  MMP2,  MMP9,  and  MT1-MMP[47].  The 
transmembrane  metalloprotease  MT1-MMP  is  essential 
for invadopodia proteolytic activity: knockdown of MT1-
MMP in multiple cell lines almost completely eliminates 
associated matrix degradation[19, 48]. In addition, 
recent work has also elucidated the vital role of MT-
MMPs in mediating invasion through three-dimensional 
matrices[49].The central role of MT-MMPs in mediating 
extracellular proteolysis at invadopodia could be due to 
either  its intrinsic collagenase/gelatinase activity or via 
activation of soluble MMPs by MT1-MMP[50]. There is 
also evidence that hydroxymate metalloprotease inhibitors 
prevent not only ECM proteolysis, but also invadopodia 
formation through an unknown mechanism[19]. 
As  cancer  cells  must  invade  through  both 
basement membranes and the ECM during metastasis, 
metalloproteases were quickly recognized as appealing 
targets  to  inhibit  metastasis.  Although  results  were 
promising in preclinical models, metalloprotease inhibitors 
have universally failed in clinical trials[51]. Once again, 
clinical trials with metalloprotease inhibitors to date have 
invariably used unselected patient populations, often with 
late-stage  disease.  Additionally,  early  metalloprotease Oncotarget 2011; 2:  562 - 568 566 www.impactjournals.com/oncotarget
inhibitors were broad-spectrum inhibitors of multiple 
metalloproteases and often had acute toxicities that 
severely limited therapeutic doses[51]. MMPs may also 
play anti-tumor functions in many tumors, as well. For 
example,  MMP8-/-  mice  developed  more  papillomas 
upon carcinogen treatment[52].In recent years, there has 
been a reemergence of interest in more targeted inhibition 
of metalloproteases. In particular, the fully human 
monoclonal antibody DX-2400 (Dyax Corp.) that targets 
MT1-MMP, has shown great promise in preclinical models 
in  inhibiting  invasiveness  of  cancer  cell  lines[53].  In 
addition, a novel class of metalloprotease inhibitors, triple-
helical transition state analogues, specifically targets the 
gelatinase and collagenase activities of metalloproteases 
(specifically MMP2 and 9)[54]. Clinically addressing the 
role of metalloproteases in breast cancer metastasis will 
involve not only designing trials to maximize the impact 
of the therapeutics, but also finding novel inhibitors with 
greater specificity and fewer negative side-effects.
conclusions
In order to directly target metastasis, essential 
regulators of the metastatic process must be identified. In 
addition, these targets should ideally be kinases or proteases 
with moieties amenable to chemical inhibition. Although 
EMT is beginning to be recognized as a key player in 
breast cancer, promising targets of inhibition regulating 
this  process  have  been  lacking.  Our  identification  of 
PDGFRα and invadopodia as essential mediators of EMT-
induced metastasis opens the door for clinical intervention 
of pathways regulating invadopodia function. These 
pathways include Src kinase, PDGFRα, and invadopodia-
specific  proteases.  In  order  to  test  the  hypothesis  that 
inhibiting such pathways is effective, clinical trials most 
likely benefit from careful selection of patient populations 
based on our knowledge of invadopodia regulation. 
In  addition,  for  both  PDGFRα  and  metalloproteases, 
generation of more selective compounds may be necessary 
to realize positive clinical outcomes. Our study suggests 
that Twist1 and PDGFRα are effective predictors, not only 
of patient survival, but also for patient selection in clinical 
trials targeting invadopodia formation and function.
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